These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31951523)

  • 1. Siponimod Chips Away at Progressive MS.
    Longbrake EE; Hafler DA
    Cell; 2019 Dec; 179(7):1440. PubMed ID: 31951523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 3. Siponimod: First Global Approval.
    Al-Salama ZT
    Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.
    Song Y; Lao Y; Liang F; Li J; Jia B; Wang Z; Hui X; Lu Z; Zhou B; Luo W; Song B
    Medicine (Baltimore); 2019 Aug; 98(34):e15415. PubMed ID: 31441835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A
    Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract]   [Full Text] [Related]  

  • 8. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
    Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
    Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod for the treatment of secondary progressive multiple sclerosis.
    Dumitrescu L; Constantinescu CS; Tanasescu R
    Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ
    CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Cree BA; Magnusson B; Rouyrre N; Fox RJ; Giovannoni G; Vermersch P; Bar-Or A; Gold R; Piani Meier D; Karlsson G; Tomic D; Wolf C; Dahlke F; Kappos L
    Mult Scler; 2021 Sep; 27(10):1564-1576. PubMed ID: 33205682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siponimod and CYP2C9 Allele Prevalence Among Blacks.
    Liu M; Obeng AO
    J Clin Pharmacol; 2020 Apr; 60(4):429-431. PubMed ID: 31701536
    [No Abstract]   [Full Text] [Related]  

  • 15. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
    Litwin T; Smoliński Ł; Członkowka A
    Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
    JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
    Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
    Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.